Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
2(9%)
Results Posted
50%(7 trials)
Terminated
1(5%)

Phase Distribution

Ph not_applicable
1
5%
Ph phase_1
2
9%
Ph phase_2
3
14%
Ph phase_3
5
23%
Ph phase_4
6
27%

Phase Distribution

2

Early Stage

3

Mid Stage

11

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
3(17.6%)
Phase 3Large-scale testing
5(29.4%)
Phase 4Post-market surveillance
6(35.3%)
N/ANon-phased studies
1(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

2

trials recruiting

Total Trials

22

all time

Status Distribution
Active(4)
Completed(14)
Terminated(2)
Other(2)

Detailed Status

Completed14
unknown2
Recruiting2
Not yet recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
2
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (11.8%)
Phase 23 (17.6%)
Phase 35 (29.4%)
Phase 46 (35.3%)
N/A1 (5.9%)

Trials by Status

completed1464%
unknown29%
recruiting29%
not_yet_recruiting29%
terminated15%
withdrawn15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT07519889

Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke

Not Yet Recruiting
NCT07111559Phase 4

Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial

Recruiting
NCT05395351

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

Completed
NCT06663631Phase 1

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Recruiting
NCT05401149

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Completed
NCT05395338

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

Completed
NCT05700591Phase 3

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Completed
NCT06433011Not Applicable

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

Not Yet Recruiting
NCT04248868Phase 3

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

Completed
NCT03927508Phase 1

First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism

Completed
NCT04797013Phase 3

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

Completed
NCT03740958Phase 4

Argatroban Plus R-tPA for Acute Ischemic Stroke

Completed
NCT03394950Phase 4

Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

Completed
NCT02854592

Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset

Completed
NCT01827046Phase 3

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Completed
NCT03506009Phase 4

Argatroban Plus r-tPA for Posterior Circulation Infarction(AR-PCI)

Terminated
NCT02338466Phase 2

Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion

Withdrawn
NCT02472574Phase 2

Dose-effect Relationship of Rt-PA on ICH Evacuation

Unknown
NCT00894803Phase 2

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Completed
NCT00148460Phase 3

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22